Tag:

Collegium Pharmaceutical

Latest Headlines

Collegium Pharma scores $22M round for abuse-preventing painkiller in Phase III

February 22, 2012

Venture backers have rallied behind Collegium Pharmaceutical to continue a late-stage trial for its extended-release version of oxycodone.

THE LIBRARY: WEBINAR

Getting the most PoC data in Phase I cancer studies

| June 12, 11am ET/ 8am PT

The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!

MORE ITEMS

EVENTS

MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
What's your BIO?June 18-21, 2012 — Boston, MA

MORE EVENTS

Press Releases

Featured Jobs

Scientist II Job
Yoh - Niskayuna, NY, USA
Microbiology Scientist
C3 Jian - Marina Del Rey, CA
Senior Controls Engineer Job
Celgene Corporation - Phoenix, AZ, US
Director, Human Resources
TESARO - Waltham, MA
Pharmacist (Drug Safety and Product Information) Job
Yoh - Durham, NC, USA

Collegium Pharmaceutical

Latest Headlines

Latest Headlines

Collegium Pharma scores $22M round for abuse-preventing painkiller in Phase III

THE LIBRARY: WEBINAR

EVENTS

Press Releases

Featured Jobs

A publication of FierceMarkets

The FierceMarkets Network:

Telecom

Healthcare

Government

Energy

Life Sciences

Enterprise IT

Finance

Collegium Pharmaceutical

Latest Headlines

Latest Headlines

Collegium Pharma scores $22M round for abuse-preventing painkiller in Phase III

Related Tags